Table 1.

Clinical characteristics of the patients

	Number/mean ± SD
Age (years)	68±11
Men	65
Women	42
IRB	35
ARBs–IRB switch	72
Type I DM	3
Type II DM	104
Insulin treatment	16
Diabetic duration (years)	14±8
BMI baseline (kg/m2)
IRB	24.1±3.4
ARBs–IRB switch	24.4±3.7
Total	24.3±3.6
SBP baseline (mmHg)
IRB	137±8.5
ARBs–IRB switch	134±6.0*
Total	135±7.0
DBP baseline (mmHg)
IRB	82±7.9
ARBs–IRB switch	79±5.2**
Total	80±6.4
Glucose baseline (mg/dL)
IRB	165±72
ARBs–IRB switch	145±38*
Total	152±52
HbA1c baseline (%)
IRB	6.8±1.2
ARBs–IRB switch	6.6±0.98
Total	6.7±1.1
HDL-C baseline (mg/dL)
IRB	62±19
ARBs–IRB switch	56±17
Total	58±18
LDL-C baseline (mg/dL)
IRB	116±22
ARBs–IRB switch	107±23*
Total	110±23
TG baseline (mg/dL)
IRB	142±67
ARBs–IRB switch	139±77
Total	140±74
SCr baseline (mg/dL)
Male	0.86±0.30
Female	0.65±0.14
IRB	0.75±0.31
ARBs–IRB switch	0.80±0.29
Total	0.79±0.27
eGFR baseline (mL/min/1.73 m2)
Male	74±22
Female	72±19
IRB	76±21
ARBs–IRB switch	72±21
Total	73±21
SUA baseline (mg/dL)
Male	5.7±1.1
Female	4.7±1.0
IRB	5.0±1.0
ARBs–IRB switch	5.4±1.1*
Total	5.3±1.1
Diabetic nephropathy
Stage I	11
Stage II	50
Stage III	19
Stage IV	2
Myocardial disease	7
Cerebrovascular disease	7
Arteriosclerosis	2

Notes:

^*P<0.05,

^**P<0.01 versus IRB group by Student’s t-test.

Abbreviations: ARB, angiotensin II receptor blockers; BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HbA_1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; IRB, irbesartan; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SCr, serum creatinine; SD, standard deviation; SUA, serum uric acid; TG, triglyceride.